Sonal Paul, MD is a medical oncologist and hematologist with a strong background in clinical research and patient education. Her clinical interests include the treatment of gastrointestinal tract cancers, such as cancers of the esophagus, stomach, liver, colon, and rectum.
Dr. Paul is actively involved in research projects as the principal investigator for multiple clinical trials focusing on gastrointestinal therapeutics. These trials aim to advance the understanding and treatment of gastrointestinal cancers.
She has written research articles on a variety of topics, including the role of immune checkpoint inhibitors in gastrointestinal malignancies, the genomic landscape of SMARCA4 alterations in lung cancer patients, and the efficacy of convalescent plasma in hospitalized COVID-19 patients.
Dr. Paul pursued her undergraduate education at the University of Maryland Baltimore County, where she earned a Bachelor of Science degree in Biological Sciences with a Minor in Psychology. She then attended Ross University School of Medicine, graduating with honors. Following medical school, Dr. Paul completed her Internal Medicine residency at New York Presbyterian Brooklyn Methodist Hospital – Weill Cornell Medicine. During her residency, she received additional training at the Memorial Sloan Kettering Cancer Center in New York. Subsequently, she pursued a fellowship in Hematology and Oncology at New York Presbyterian Brooklyn Methodist Hospital – Weill Cornell Medicine, where she also served as the Chief Fellow.
Dr. Paul is deeply committed to enhancing oncology care through personalized cancer treatment and patient education. Her dedication to tailoring treatment plans and empowering patients with knowledge underscores her mission to improve outcomes and foster a sense of empowerment in those she cares for. Through her multifaceted approach, Dr. Paul continues to make significant strides in advancing oncology care, ensuring that each patient receives the highest standard of personalized treatment and support.
- Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A,Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M,Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun.2022 Jul;6(7):1776-1785. doi: 10.1002/hep4.1927. Epub 2022 Apr 28. PMID: 35481940; PMCID: PMC9234627.
- Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Bégin,Philippe et al. Nature Medicine. 2021 Sep 9. doi: 10.1038/s41591-021-01488-2. Epub ahead of print. PMID:34504336.
- Imaging Conundrum of Granular Cell Astrocytoma: A Case Report. Zhu F, Paul S, Miller E, Kumarasinghe C, Mokhtar, B, Kalavar M. Scirea J Cli Med. 2021 Jan 26: 6(2):61-75.
- ABO Blood Type and Outcomes in a Diverse COVID-19 Infected Population. Paul S, Patel N, Kumarasinghe C, Nimkar N, Singh A, Vishnuvardhan N, Ashraf F, Mazloom A, Kodama R, Kalsi A, Usta S, Ashfaq A, Gregos P,Khan U, Weingarten J, Patel E. Blood (2020) 136 (Supplement 1): 27–28 doi: https://doi.org/10.1182/blood-2020- 142943
- Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. Mazloom A, Ghalehsari N, GazivodaV, Nimkar N, Paul S, Gregos P, Rateshwar J, Khan U.J Clin Med. 2020 Aug 6;9(8):2533. doi:10.3390/jcm9082533
- The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. Schoenfeld AJ, Bandlamudi C, Lavery JA, Montecalvo J, Namakydoust A, Rizvi H, Egger J, Concepcion CP, Paul S, Arcila ME, Daneshbod Y, Chang J, Sauter JL, Beras A, Ladanyi M, Jacks T, Rudin CM, Taylor BS, Donoghue MTA, Heller G, Hellmann MD, Rekhtman N, Riely GJ.Clin Cancer Res. 2020 Nov 1;26(21):5701-5708. doi: 10.1158/1078-0432.CCR-20-1825. Epub 2020 Jul 24.PMID: 32709715
- Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. Fessas P, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Rafeh Naqash A, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Benevento F, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Rimassa L, Ang C, Marron T, Pinato DJ.J Immunother Cancer. 2020 Aug;8(2):e001033. doi: 10.1136/jitc-2020- 001033.PMID: 32868393
- Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. Pinato DJ, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Fessas P, Nimkar N, Bettinger D, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Lozano-Kuehne J, Rimassa L, Ang C, Marron TU.J Immunother Cancer. 2020 Oct;8(2):e000726. doi: 10.1136/jitc-2020- 000726.PMID: 33028690
- Racial Disparities with Esophageal Cancer Mortality at a High-Volume University Affiliated Center: An All ACCESS Invitation. Renelus BD, Jamorabo DS, Kancharla P, Paul S, Dave N, Briggs WM, Peterson SJ.J Natl Med Assoc. 2020 Oct;112(5):478-483. doi: 10.1016/j.jnma.2019.04.005. Epub 2019 May 7.PMID: 31072644
- Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH.Cancers (Basel). 2020 Jul 10;12(7):1862. doi: 10.3390/cancers12071862.PMID: 32664319
- Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Jun T, Ozbek U, Dharmapuri S, Hardy-Abeloos C, Zhu H, Lin JY, Personeni N, Pressiani T, Nishida N, Lee PC, Lee CJ, Hildebrand H, Nimkar N, Paul S, Fessas P, Naeem M, Bettinger D, Khan U, Saeed A, Huang YH, Kudo M, Rimassa L, Marron TU, Pinato DJ, Ang C.Ther Adv Med Oncol. 2021 Apr 28;13:17588359211010937. doi: 10.1177/17588359211010937. eCollection 2021.PMID: 33995594
- The impact of disinfectant cap implementation on central line-associated bloodstream infections. Palkar V, Patel V, Jacob C, Paul S, Andrade J.Infect Dis (Lond). 2016 Aug;48(8):646-8. doi: 10.3109/23744235.2016.1174339. Epub 2016 May 11.PMID: 27167407
Oral Presentations
- Outcomes in COVID-19 Patients on Treatment Dose Anti-Coagulation Compared to Prophylactic Dose Anti-Coagulation, 62nd Annual American Society of Hematology Meeting and Exposition, 2020
- Clinical Course and Outcomes of Sickle Cell Disease Patients with COVID-19, 62nd
Annual American Society of Hematology Meeting and Exposition, 2020 - Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients, 62nd Annual American Society of Hematology Meeting and Exposition, 2020
- Broken Heart from Broken Muscle: Non-Statin Induced Rhabdomyolysis causing Takotsubo Cardiomyopathy, 11th Annual Symposium Gender Differences in Cardiovascular Disease, 2018
Poster Presentation
- Safety Rounders as an Effective Mechanism to Prevent Inpatient Falls, New York Chapter of the American College of Physicians Annual Meeting 2017